US Stocks To Watch To Diversify Away From AI Mania

There is a paradox sitting right in the middle of the 2026 US stock market. The AI trade is genuinely exciting. The companies at the center of it are genuinely making a mark. And yet, the more capital floods into that trade, the more it quietly creates opportunity elsewhere. 

Seven companies now make up 32.5% of the entire S&P 500. The top ten account for nearly 40% of the index. When a $2 trillion pocket of the market can fall in a matter of weeks, as the Magnificent 7 did in early June 2026, portfolios built almost entirely on that concentration learn an uncomfortable lesson fast. The question isn't whether to own AI. It's whether owning only AI makes sense.

Let's break down which non-AI US stocks deserve serious attention right now, why the market has been ignoring them, and what the numbers actually say about each one.

The Mania Shadow Effect: A Framework for Finding What the Market Is Missing

When one investment theme gets loud enough, it does something interesting to everything around it. Portfolio managers rotate into the hot trade. Media attention gets consumed by a single story. Passive fund flows mechanically push money toward what has already gone up. The result is not just that AI stocks get expensive. It's that a systematic blind spot opens up across entire sectors.

Think of it like this. Imagine you're watching a cricket match under floodlights, and one player is standing in the direct beam of the brightest light on the ground. Everyone is looking at that player. The other ten? Still playing, still contributing, still capable of winning the match. Just not visible from where most people are standing.

This is what we're calling the Mania Shadow Effect. The AI trade has been running the brightest light in the market for the better part of three years. And in that shadow, some genuinely good businesses have been underpriced, ignored, or misread by a market that simply isn't paying attention.

There are four types of shadow stocks worth hunting for right now:

1. The Distressed Turnaround: A brand or business that stumbled on its own execution and is being rebuilt, independent of AI's outcome.

2. The Re-Rating Play: A genuine growth story that got thrown out with the bathwater when its sector turned cold.

3. The Structural Demand Bridge: A non-tech company that actually benefits from the same macro forces driving AI, but gets none of the valuation credit for it.

4. The Boring Compounder: A business with near-certain earnings power that simply isn't interesting enough to attract attention in a mania market.

Four stocks, four sectors, four different arguments. None of them guaranteed. All of them worth understanding.

Nike (NKE) Stock Analysis | Consumer Discretionary | The Distressed Turnaround

Nike is not an AI story. It's not even a technology story. It's a brand story, and right now, it's not a good one. Which is exactly the point.

In its fourth-quarter fiscal 2026 earnings call, Nike CEO Elliott Hill declared that there has been "nothing normal" about the retail landscape since he took the job, acknowledging continued operational volatility as the brand's multi-year turnaround drags on. Revenue declined 1.1% year-over-year in the quarter, and the primary drag was Nike Sportswear and Jordan Streetwear, both of which fell in the double digits.

The turnaround narrative under Hill does have some early signs of life. North America grew 9% in Q2 fiscal 2026. But RBC Capital recently pushed its expectations for meaningful revenue recovery out to 2027 rather than 2026, and lowered profit forecasts for 2027 and 2028.

So why look at this at all?

Here is the argument. Nike is one of perhaps ten or fifteen brands on earth that transcends geography, generation, and income level. The Swoosh has survived multiple management mistakes, multiple competitive cycles, and multiple macro downturns before. The current problem, excessive dependence on lifestyle and retro silhouettes like the Air Force 1 and Dunk, plus a strategic overcorrection toward direct-to-consumer that broke wholesale relationships, is a self-inflicted wound. Those are fixable.

The setup heading into Nike's Q4 and full-year FY2026 results was described by analysts as "straightforward to describe and genuinely difficult to handicap." The "Win Now" turnaround has produced early signs of stabilization but not yet the revenue acceleration or margin recovery that would justify multiple expansion.

Think of this like the Tata Motors situation a decade ago. The company was carrying a troubled Jaguar Land Rover acquisition, posting weak numbers, and the stock had been forgotten. Patient investors who understood what the brand franchise was worth eventually got rewarded. Brand trough situations tend to be mean-reverting because great brand equity rarely disappears, it just gets temporarily unlocked by bad strategy.

The Valuation Argument: A back-of-envelope normalized earnings exercise. Nike's five-year average EPS before the current reset was approximately $3.50. Apply a recovery multiple of 25x (Nike historically traded at 30x+), and you get a fair value case somewhere around $87. Today's price of $41 implies the market doesn't believe that recovery happens. That's not unreasonable skepticism. But it does mean you're getting paid to wait for evidence.

Bear Case: The turnaround drags into 2028. China's headwinds worsen. New CFO disrupts strategy. Meanwhile Adidas, On Running, and HOKA continue to take share in the premium athletic segment. If EPS shows no recovery, the current multiple is actually not cheap.

2. Novo Nordisk (NVO) Stock Analysis | Healthcare | The Re-Rating Play

In 2024, Novo Nordisk was briefly Europe's most valuable company. Ozempic was a cultural phenomenon. Wegovy was rewriting the weight-loss category. The stock was trading at above $120.

Today, NVO trades near $49, down almost 60% from those peaks. The market has moved from irrational exuberance to something close to irrational pessimism. The truth, as usual, sits somewhere in the middle.

The most important data point from Novo's Q1 2026 earnings was not on the income statement. According to Novo Nordisk's earnings call, close to 80% of Wegovy pill users are GLP-1 treatment-naïve, meaning they had never been on a GLP-1 drug before. By the week ending April 17, weekly prescriptions for the Wegovy pill reached 207,000.

That 80% figure reframes the entire competitive narrative. For much of 2025, the thesis against Novo was that Eli Lilly was eating its lunch. And Lilly has been winning. Lilly's Mounjaro and Zepbound posted sales growth of 125% and 80% respectively in the period when Novo reported Ozempic sales down 8%. That's a real competitive pressure.

But if 80% of Wegovy pill users are entirely new patients who were not on any GLP-1 before, that's market expansion, not market share loss. The pill format is opening a completely new customer segment: people who were unwilling or unable to inject.

Here is an analogy that might resonate. When India moved from insulin injections to oral diabetes drugs like metformin, it wasn't a case of one drug killing another. It was a case of the pill format unlocking a massive previously untreated population. That's what the oral Wegovy appears to be doing in the US.

Multiple valuation frameworks suggest Novo Nordisk may be trading well below intrinsic worth. Simply Wall St's model suggests a fair P/E of approximately 23.6x for Novo given its size, margins, and risk profile, a figure materially above the current multiple. Medicare's decision to extend coverage to certain GLP-1 weight loss drugs adds a demand tailwind that may not be fully reflected in current pricing.

The Valuation Argument: At 11.7x earnings, Novo trades at a 33% discount to the US biotech sector average of 17.6x. If Wegovy pill momentum continues and the market re-rates the stock even back to a 17x multiple, using the same earnings base, that's approximately a 45% move in the stock. That's before any earnings growth.

Bear Case: Eli Lilly continues widening its lead. CagriSema, Novo's next-generation combination drug, disappointed in its REDEFINE 4 trial against Lilly's tirzepatide. A deeper setback in the pipeline could push the re-rating out further. The 2026 guidance of declining revenues is a real negative for a company the market once priced for unlimited growth.

3. Freeport-McMoRan (FCX) Stock Analysis | Materials | The Structural Demand Bridge

Here is the one stock on this list where the argument for diversification away from AI contains a delicious irony. Copper may be the single best non-AI bet in the market right now. And the primary reason copper is in structural deficit is precisely because AI is eating up the world's copper supply.

Think about it this way. Every AI data center being built requires massive amounts of copper. For power delivery. For cooling systems. For cabling. For grid infrastructure. JPMorgan estimates a single large AI data center can require up to 50,000 tonnes of copper. J.P. Morgan projects total data center copper demand to reach 475,000 metric tonnes annually in 2026. And according to S&P Global, global copper demand will surge from approximately 28 million metric tons in 2025 to more than 42 million metric tons by 2040, a roughly 50% increase, driven by electrification, EVs, and AI infrastructure simultaneously.

The supply side cannot keep up. The copper market was roughly balanced in 2025, but mine supply was severely disrupted and will likely create a deficit in 2026. Permitting timelines for new copper mines average 15 to 17 years from discovery to production, and the discovery pipeline is weak, with only 5% of major copper deposits found in the last decade.

Freeport-McMoRan is the world's largest publicly traded copper producer. That makes it the clearest listed equity play on the structural copper thesis.

At $61, an independent analyst rates FCX as Hold because valuation is stretched for 2026, but calls it more attractive in 2027-2028 if operational recovery at Grasberg materializes. The mine's leach innovation could deliver 300-400 million pounds per year of copper by 2026-2027 and up to 800 million pounds by 2030, representing capital-efficient growth at low additional cost.

The Grasberg mine in Indonesia is the heart of Freeport's story. It's one of the largest copper and gold deposits on earth. When it's running well, it's a cash machine. When it isn't, the stock gets punished. The current phase involves resuming phased restart operations that were disrupted by a mud intrusion in 2025. In Q1 2026, Freeport’s consolidated copper sales fell year on year as Grasberg continued its phased recovery. However, US copper sales increased and total sales came in above the company’s earlier January estimate.

The copper-AI connection is what makes this unique among diversification ideas. You're not betting against AI with FCX. You're betting that the physical infrastructure that runs AI has to be built from something, and that something is copper. Even if NVIDIA's stock halves tomorrow, the world's data centers still need to be wired. S&P Global's study, published January 8, 2026, found that the "accelerating pace of electrification" positions copper as a "strategic resource" whose supply shortfall poses "systemic risk for global industries, technological advancement and economic growth" unless significant adjustments are made.

The Valuation Argument: FCX's earnings are directly sensitive to copper prices. At copper around $13,000 per tonne (2026 levels), consensus EPS is ~$2.32. At $4.50-5.00/lb copper (roughly $9,900-11,000/tonne), which some analysts consider conservative given structural deficits, EPS could be closer to $1.50-1.80. At higher copper prices, the upside is substantial. This is essentially a levered call on copper prices with a balance sheet (0.5x net debt/EBITDA) that gives you room for error.

Bear Case: A sharp slowdown in Chinese construction and manufacturing demand could soften copper prices meaningfully. China accounts for roughly half of global copper demand. If Beijing's economy disappoints, FCX's earnings get hit quickly. Additionally, Grasberg execution risk remains. This is a mine, not a software company. Things go wrong underground.

4. JPMorgan Chase (JPM) Stock Analysis | Financials | The Boring Compounder

This one requires the least creative argument. JPMorgan is simply very good at being a bank.

In Q1 2026, JPMorgan Chase reported net income of $16.5 billion and EPS of $5.94, beating Wall Street estimates of $5.51 by 7.78%. Revenue of $49.84 billion rose 10% year-over-year. Markets revenue set a record at $11.6 billion. Investment banking fees surged 28%, driven by stronger advisory and equity underwriting activity. Payments posted double-digit growth in deposits and fees.

JPMorgan has become, functionally, the HDFC Bank of the United States. Dominant market position. Fortress balance sheet. Management that thinks in decades, not quarters. Jamie Dimon's "fortress philosophy" has kept the bank both profitable and well-capitalized through multiple crises that destroyed competitors.

For full-year 2025, JPMorgan generated $57.0 billion of net income on revenue of approximately $186 billion, a managed net margin north of 30%, which is extraordinary for a regulated commercial bank with global complexity. The Q1 2026 print accelerated that trajectory, with revenue up 10% and net income up 13%, showing positive operating leverage even as the bank invests heavily in technology.

The diversification logic for JPM is different from the others. It's not a turnaround bet. It's not a re-rating play. It's a quality anchor. If the AI trade stumbles, the economy still needs credit, payments, wealth management, and investment banking. JPMorgan participates in all of those. The bank boasts a $4.9 trillion balance sheet and $2.68 trillion in deposits as of March 2026, with operations across 66 countries and more than 318,000 employees.

There is also a deregulation tailwind in the US financial sector that could improve return on equity for banks in the medium term. The Basel III capital requirement adjustments, if less onerous than initially proposed, free up capital that Dimon has historically deployed shrewdly.

Despite Q1 2026 earnings beating expectations, JPM's year-to-date price return has been only around 3%. Client investment assets grew 18% year-over-year, and assets under management grew 16% year-over-year, driven by healthy inflows.

Bear Case: Higher-for-longer interest rates could pressure loan demand and increase credit costs. A US recession would hit all of JPM's segments simultaneously. Jamie Dimon's eventual succession is the single largest key-man risk in US banking. Any signal of a leadership vacuum could trigger a significant derating.

The Bear Case Across All Four: What Are the Risks of Investing in These Four US Stocks?

This is the part that must be kept in mind for each of them:

The macro bear case is equally real. If the AI trade stumbles and takes down risk appetite broadly, all four of these stocks would likely fall too in the short term. The diversification argument is not that these stocks are uncorrelated to market volatility. It's that they are not dependent on AI valuations being sustained, that their business models stand independent of whether Nvidia's P/E holds, and that over a two-to-four-year horizon, their individual stories have better defined recovery paths.

There's also the AI earnings risk worth naming directly. Perhaps the most concerning dynamic in the AI investment landscape is the disconnect between infrastructure spending and actual revenue generation. Hyperscalers committed nearly $400 billion in capital expenditure during 2025, while enterprise AI generates approximately $100 billion in actual revenue. This four-to-one spending-to-revenue ratio raises fundamental questions about the sustainability of current investment levels.

If that spending-to-revenue ratio doesn't close in the next 18-24 months, the AI trade will face a serious earnings credibility problem. That's not a reason to short AI. But it is a reason to not be concentrated entirely within it.

Our Take

We think the Mania Shadow Effect is real in 2026. The market's attention has been so narrowly focused on AI that an unusual number of quality businesses have been underpriced or under-analyzed. That creates a setup for patient investors willing to hold through continued near-term pain.

The most interesting risk-reward picture in our view, based purely on the fundamental analysis, is Novo Nordisk, where a genuine structural growth franchise is being priced at a cyclical reset multiple, and Freeport-McMoRan, where the copper structural deficit is not a thesis but a mathematical inevitability that is already showing up in smelter pricing at zero treatment charges.

Nike is the highest-risk, potentially highest-reward bet on this list. Great brand, real problems, real recovery possibility. The turnaround timeline risk is genuine and the recent Q4 FY2026 results confirmed the reset is taking longer than management expected.

JPMorgan is the steadiest hand in the room. No narrative excitement, but 23% ROTCE and consistent earnings growth in any economic environment is a rare thing.

None of these are ideas to chase. They're ideas to understand, monitor, and build a view on. The goal of portfolio diversification is not to abandon what's working. It's to make sure that if what's working stops working, your entire financial life doesn't stop with it.